185 related articles for article (PubMed ID: 36737318)
1. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Getaneh AM; Li X; Mao Z; Johannesen CK; Barbieri E; van Summeren J; Wang X; Tong S; Baraldi E; Phijffer E; Rizzo C; van Wijhe M; Heikkinen T; Bont L; Willem L; Jit M; Beutels P; Bilcke J;
Vaccine; 2023 Feb; 41(9):1623-1631. PubMed ID: 36737318
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
[TBL] [Abstract][Full Text] [Related]
3. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
Li X; Hodgson D; Flaig J; Kieffer A; Herring WL; Beyhaghi H; Willem L; Jit M; Bilcke J; Beutels P;
Value Health; 2023 Apr; 26(4):508-518. PubMed ID: 36442831
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
Liu D; Leung K; Jit M; Wu JT
Vaccine; 2021 Sep; 39(39):5490-5498. PubMed ID: 34454783
[TBL] [Abstract][Full Text] [Related]
8. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
9. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
10. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.
Baral R; Higgins D; Regan K; Pecenka C
BMJ Open; 2021 Apr; 11(4):e046563. PubMed ID: 33895717
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
12. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
Lee Mortensen G; Harrod-Lui K
Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
[TBL] [Abstract][Full Text] [Related]
13. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
15. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
[TBL] [Abstract][Full Text] [Related]
16. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
17. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
[TBL] [Abstract][Full Text] [Related]
18. Respiratory Syncytial Virus-Associated Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries.
Wang X; Li Y; Vazquez Fernandez L; Teirlinck AC; Lehtonen T; van Wijhe M; Stona L; Bangert M; Reeves RM; Bøås H; van Boven M; Heikkinen T; Klint Johannesen C; Baraldi E; Donà D; Tong S; Campbell H;
J Infect Dis; 2022 Aug; 226(Suppl 1):S22-S28. PubMed ID: 35023567
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
